| Literature DB >> 31976343 |
Ali Kasiri1, Mohammad Sadegh Mirdehghan1, Fereydoun Farrahi1, Farshad Ostadian1, Mostafa Feghhi1, Mehdi Reza Ghomi1, Aram Mohammad Jafari1, Atefeh Mahdian Rad1, Niusha Kasiri2.
Abstract
The purpose of this study was to compare the effects of propranolol, timolol and bevacizumab with betamethasone to prevent corneal neovascularization (CNV) in rabbits. This study was performed on 28 male rabbits. CNV was induced by three 7-0 silk sutures 2 mm long and 1 mm distal to the limbus. Animals were randomly divided into 4 groups of propranolol + betamethasone, timolol + betamethasone and bevacizumab + betamethasone and betamethasone alone. Eye drops were started from the first day of study. On 7th, 14th, 21st, 28th, 35th and 42nd days, vascular progression, time of neovascularization and vascular area were evaluated and compared with the control group (betamethasone alone). There was a significant reduction in the area of neovascularization in the timolol and bevacizumab groups compared to the control group (P-value = 0.05, P=0.047, respectively). Also, regarding vascular progression, there was a significant decrease in the timolol and bevacizumab groups (P-value = 0.014, P=0.002, respectively). Regarding delayed onset of neovascularization, there was a significant difference in the timolol and bevacizumab group in rabbits (P-value = 0.04, P=0.00, respectively). In conclusion, the use of timolol and bevacizumab drops besides betamethasone can delay neovascularization and decrease the length of corneal vascularization in rabbits.Entities:
Keywords: Betamethasone; Bevacizumab; Corneal Neovascularization; Propranolol; Timolol
Year: 2020 PMID: 31976343
Source DB: PubMed Journal: Med Hypothesis Discov Innov Ophthalmol ISSN: 2322-3219